{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-160340","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2023-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.335678+00:00","generated_at":"2026-06-14T07:27:59.112009+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"IN8bio Phase 1 INB-200 data shows 100% of GBM patients exceed historical median PFS","bullets":["100% (8/8) patients exceeded historical median PFS of 4-7 months; two patients from three-dose cohort remain progression-free at 23.5 and 19.4 months.","No treatment-related SAEs, DLTs, CRS, or ICANS reported; common TEAEs mild and linked to temozolomide.","Cohort 1 PFS ranged 7.4–11.9 months; Cohort 3 first patient had 7.1 months PFS with no brain progression.","Company on track to complete Phase 1 enrollment in 2023; further updates expected later this year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-160340","json":"https://secwatch.observer/filing/0001193125-23-160340.json","markdown":"https://secwatch.observer/filing/0001193125-23-160340.md","text":"https://secwatch.observer/filing/0001193125-23-160340.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523160340/0001193125-23-160340-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523160340/d447037d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T07:27:59.112009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}